Morepen Laboratories Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹746 Cr +81.1% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
ML

Morepen Laboratories Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Morepen Laboratories Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹570Cr
+34.1% YoY
+17.5% QoQ
Net profit
₹56Cr
+409.1% YoY
+250% QoQ
Margin
14%
+8 pp YoY
+9 pp QoQ

Morepen Laboratories Ltd Q1 FY27 key numbers

Revenue
Quarterly revenue reported: Rs. 575.31 Cr.

As stated in Morepen Laboratories Ltd's Q1 FY27 investor presentation · published 25 Sept 2026. Reported figures, not investment advice.

Based on Morepen Laboratories Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹117
Market cap₹6.6K Cr
P/E56.4

The short version

Quarterly revenue reported: Rs. 575.31 Cr (Page 4). EBITDA for Q1 FY27: Rs. 87.72 Cr, up 207% YoY.

From Morepen Laboratories Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

- Quarterly revenue reported: Rs. 575.31 Cr (Page 4) - Year-on-year (YoY) revenue growth: +34% (Page 4,7) - EBITDA for the quarter: Rs. 87.72 Cr, up 3x YoY with 15%+ margin (Pages 3,4,7,17) - PAT for the quarter: Rs. 56.35 Cr, +394% YoY (Pages 4,7) - Export revenue growth: +111% YoY (Pages 3,7) - Commercial CDMO dispatches: Rs. 58 Cr, with 34% YoY growth (Pages 3,4,17) - API business growth: 31% YoY (Page 8) - Capacity expansion planned from 600 KL to 1200 KL by FY30 (Page 11) Explicit outlook (Page 18): - Near term: Improve commercial CDMO supplies, API profitability recovery, capacity utilization

2 more points from Morepen Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capacity expansion roadmap from 600 KL to 1200 KL (Page 17).
  • Manufacturing capacity scaling in four phases:
  • Phase 1: 535 KL (completed by Q4 FY26)
  • Phase 2: 600 KL (Q2 FY27)
  • Phase 3: 800 KL (FY29)
  • Phase 4: 1000 KL (Q2 FY28) and 1200 KL (FY30) (Page 11).

2 more points from Morepen Laboratories Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It mentions: - The CDMO mandate entered commercial supplies with Rs. 58 Cr commercial CDMO dispatches completed (Page 17). - The CDMO journey has entered commercial scale with recurring revenues and long-duration customer programmes (Page 6).

2 more points from Morepen Laboratories Ltd's call on order book

Create a free account to keep reading this call

Morepen Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Morepen Laboratories Ltd Q1 FY27 results — key figures

Morepen Laboratories Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue570425+34.1%485+17.5%
Operating profit (EBITDA)8324+245.8%24+245.8%
Operating margin14%6%+8 pp5%+9 pp
Profit before tax7516+368.8%23+226.1%
Net profit (PAT)5611+409.1%16+250%
EPS (₹)1.030.20+415%0.29+255.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹89 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Morepen Laboratories Ltd Q1 FY27 results?

Quarterly revenue reported: Rs. 575.31 Cr (Page 4). EBITDA for Q1 FY27: Rs. 87.72 Cr, up 207% YoY.

What is Morepen Laboratories Ltd share price analysis?

Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.

Is Morepen Laboratories Ltd planning capital expenditure?

Capacity expansion roadmap from 600 KL to 1200 KL (Page 17).

Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.